Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Total peripheral resistance

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    133 result(s) found for: Total peripheral resistance. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2004-002601-69 Sponsor Protocol Number: CA180-013 Start Date*: 2005-01-25
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase II Study to Determine the Activity of BMS-354825 in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease that is Resistant to High Dose Ima...
    Medical condition: Chronic phase Philadelphia chromosome-positive chronic myeloid leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) SE (Completed) FI (Completed) GB (Completed) IE (Completed) IT (Completed) BE (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-003449-17 Sponsor Protocol Number: MC/PR/15009/001/11 Start Date*: 2012-05-31
    Sponsor Name:CHIESI
    Full Title: A 12-week, multicenter, randomized, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster NEXThaler (beclomethasone dipropionate 100 µg plus formotero...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004460-66 Sponsor Protocol Number: KARAASS-1 Start Date*: 2014-04-01
    Sponsor Name:Jørgen Jeppesen
    Full Title: Oral potassium supplementation in healthy men - interactions with the renin-angiotensin-aldosterone system and the sympathetic nervous system
    Medical condition: Blood pressure regulation and hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004866 10008393 Change in blood pressure LLT
    16.1 100000004865 10053967 Potassium supplementation LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-003249-16 Sponsor Protocol Number: PML_DOC_1102 Start Date*: 2012-01-06
    Sponsor Name:University Hospital of Antwerp
    Full Title: OPEN-LABEL, PROSPECTIVE EXPLORATORY STUDY TO ASSESS THE EFFECTS OF FORMOTEROL AND BECLOMETASONE DIPROPIONATE COMBINATION THERAPY USING A DPI DEVICE ON CENTRAL AND PERIPHERAL AIRWAY DIMENSIONS IN AS...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002281-70 Sponsor Protocol Number: 2014-002281-70 Start Date*: 2015-02-19
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV-1?infected patients (<100 CD4+ T cells/?L) taking antiretroviral regimens based on dolutegravir or ritonavir-boosted daru...
    Medical condition: tratement HIV infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003409-23 Sponsor Protocol Number: MERMAID1 Start Date*: 2023-12-12
    Sponsor Name:Medical University of Warsaw
    Full Title: Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia. with resistance, relapse or detectable measurable residual disease. Phase I/I...
    Medical condition: B-cell acute lymphoblastic leukemia. with resistance, relapse or detectable measurable residual disease.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066109 Precursor B-lymphoblastic leukemia acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002006-39 Sponsor Protocol Number: ESTER Start Date*: 2016-11-14
    Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"
    Full Title: Study on Efficacy and safety of an early proactive Switch To ElvitegraviR/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in patients with a primary HIV-1 infection
    Medical condition: Treatment of HIV infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005792-25 Sponsor Protocol Number: R04341 Start Date*: 2017-12-22
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: Feasibility study on the effects of L-citrulline on uteroplacental and cardiovascular function in hypertensive pregnant women
    Medical condition: The medical condition that is to be investigated in this study is essential hypertension in pregnant women. In this study it is defined as diastolic BP of ≥90 mmHg (average of two clinic readings) ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10070538 Gestational hypertension PT
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10036485 Pre-eclampsia PT
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10014129 Eclampsia PT
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002695-45 Sponsor Protocol Number: 15-156 Start Date*: 2018-05-16
    Sponsor Name:RWTH Aachen University represented by the Rector, himself, represented by the Dean of the Medical Faculty
    Full Title: Effect of Empagliflozin on Cardiac Output in Patients with Acute Heart Failure (EMPA Acute Heart Failure)
    Medical condition: Patients with acute heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006837-28 Sponsor Protocol Number: PML_DOC_0804 Start Date*: 2008-12-08
    Sponsor Name:University Hospital Antwerp; Department Respiratory Medicine
    Full Title: Double blind, randomized, placebo-controlled, two-way crossover, pilot study to assess the effect of high dose N-acetylcysteine on small airways and on inflammation and oxidative stress in COPD pat...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003946-13 Sponsor Protocol Number: PML_NAC_01 Start Date*: 2007-09-05
    Sponsor Name:University Hospital Antwerp; Department Respiratory Medicine
    Full Title: Double blind, randomized, placebo-controlled, two-way crossover, pilot study to assess the effect of high dose N acetylcysteine on small airways and on inflammation and oxidative stress in COPD pat...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004241-32 Sponsor Protocol Number: EDOLAS Start Date*: 2020-02-07
    Sponsor Name:SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI
    Full Title: Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression
    Medical condition: HIV-1 infected individuals currently taking an INSTI-based three-drug first-line regimen for less than 18 months and who have been virologically suppressed with HIV-1 RNA <50 copies/mL
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-001818-41 Sponsor Protocol Number: CAMN107A2109 Start Date*: 2006-01-04
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio abierto, multicéntrico de acceso expandido de AMN107 oral en pacientes adultos con Imatinib (Glivec®/Gleevec®) para leucemia mieloide crónica intolerante o resistente en crisis blástica o f...
    Medical condition: Leucemia mieloide crónica en fase acelerada, en crisis blástica y en fase crónica Chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) IE (Completed) CZ (Completed) SE (Completed) DK (Completed) BE (Completed) HU (Completed) AT (Completed) DE (Completed) PT (Prematurely Ended) GR (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000881-35 Sponsor Protocol Number: CLBH589B2202 Start Date*: 2007-01-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, multicentre study of oral LBH589 in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors
    Medical condition: Adult patients with chronic phase Ph+ CML whose disease is resistant following treatment with at least two BCR-ABL tyrosine kinase inhibitors (i.e. imitinib, nilotinib, or dasatinib).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009015 Chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) NL (Completed) FR (Completed) GB (Prematurely Ended) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002011-27 Sponsor Protocol Number: CLBH589B2211 Start Date*: 2007-01-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, multicentre study of oral LBH589 in patients with accelerated phase or blast phase (blast crisis) chronic myeloid leukemia with resistant disease following treatment with at least two B...
    Medical condition: Patients with accelerated phase (AP) or blast crisis (BC) CML who have disease-resistance following treatment with at least two BCR-ABL tyrosine kinase inhibitors (i.e., imatinib, nilotinib, or das...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009015 Chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DK (Completed) FR (Prematurely Ended) DE (Completed) NL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002766-20 Sponsor Protocol Number: CAUY922A2101 Start Date*: 2009-02-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in...
    Medical condition: Dose-expansion study to assess safety, tolerability & efficacy: -One arm (MTD expansion) will enroll advanced cancer patients (other than breast carcinoma). -Two arms (phase II) to assess response ...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-003109-73 Sponsor Protocol Number: TL-895-203 Start Date*: 2021-02-15
    Sponsor Name:Telios Pharma, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with KRT-232 in Subjects with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
    Medical condition: Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10081514 Acute myeloid leukemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) AT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011816-39 Sponsor Protocol Number: Start Date*: 2010-01-21
    Sponsor Name:Imperial College London
    Full Title: A randomised, open label, prospective study to assess two different therapeutic strategies following first treatment failure in HIV-1 infected subjects. ‘The First Failure Study’ : ‘FAST’
    Medical condition: HIV
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002517-36 Sponsor Protocol Number: CA180-015 Start Date*: 2004-12-27
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase II Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib...
    Medical condition: Lympohid blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) FI (Completed) GB (Completed) DK (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002515-89 Sponsor Protocol Number: CA180-005 Start Date*: 2004-12-27
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate Revised Protocol 01: Incorporates Amendment 03 and Admini...
    Medical condition: Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) FI (Completed) GB (Completed) IT (Completed) DE (Completed) BE (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 13:27:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA